CClinicalTrials.gg
TerminatedNCT02524938PoGlyDRIUpdated Feb 10, 2023

Dietary Polyphenols and Glycation in Renal Insufficiency

An interventional study of Chlorogenic Acid (CGA) enriched coffee and Conventional coffee in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic, sponsored by NHS Greater Glasgow and Clyde. Terminated at 2 sites in United Kingdom. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by NHS Greater Glasgow and Clyde · Not applicable, Interventional, and Treatment

Why this study was terminated
Failure to recruit due to human resourcing
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of kidney failure, with high levels of glycohaemoglobin (HbA1c) presenting a sharper decline in renal function and an increase in the risk of mortality and end-stage renal disease (ESRD). Polyphenols may improve renal insufficiency in patients with diabetes with chlorogenic acids (CGA) one of the principle polyphenol groups in the diet - coffee/tea, stone fruits (especially plums/prunes) and some vegetables (artichoke, chicory). CGA (3-4 cups of coffee) has been associated with 25% lower risk of T2DM and a favourable reduction of HbA1c, blood pressure, and oxidative stress levels. This randomised controlled trial, therefore, aims to evaluate the effect of high CGA food on glycation and oxidative stress in T2DM subjects with early renal insufficiency (glomerular filtration rate of 35-60 mL/min) as well as progression of renal insufficiency and the risk of cardiovascular diseases.

The study will have two phases - phase I, an interventional study of 3 months followed by phase II, an observational study of 21 months.

In phase I, subjects will be randomized into 2 groups: CGA-enriched diet group, or control (habitual) diet group. The treatment group will be provided with a chlorogenic acid-rich food (coffee) with instructions to achieve an intake of 400 mg per day (equivalent to 3-4 coffee cups per day) for 12 weeks. The control group will receive a conventional coffee low in chlorogenic acid.

Participants will attend three sessions during phase I; baseline, 6 weeks, and 12 weeks. At baseline, general information, medical history, dietary habits and medication use will be recorded and a Food Frequency Questionnaire completed. Urine and blood samples will be collected and blood pressure, waist circumference, height and weight recorded. Participants' diet over the previous 3 days will be assessed by estimated food diary analysis.

In phase II, written dietary recommendations will be provided at three time points (months 6, 12 and 24) - treatment group to achieve a CGA-rich diet (total polyphenol intake of at least 1g per day, and at least 400mg per day of CGA) and standard dietary advice for the control group. Anthropometric/dietary data will be collected as well as blood and urine samples to assess markers of renal function, glycation and oxidative stress, and proteomic markers of cardiovascular disease, coronary artery disease and diabetes.

02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Renal Insufficiency, Chronic

Keywords

  • Dietary polyphenols
  • Protein glycation
03

In context

Renal Insufficiency

1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.

This study's enrollment of 9 is below the median of 43 across 1,504 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

NHS Greater Glasgow and Clyde is the lead sponsor of 215 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • type 2 Diabetes Mellitus
  • chronic renal insufficiency with persistent eGFR of 35-60mL/min for at least three months
  • fluent in English

Exclusion criteria

Exclusion Criteria:

  • dialysis therapy (current or previous)
  • malignancy
  • transplant recipient
  • hyperthyroidism
  • hypothyroidism
  • high dose glucocorticoids (≥250 mg)
  • body mass index (BMI) ≥ 45 kg/m2
  • special dietary requirements
  • take creatine, antioxidants or vitamin supplements
  • smoker
  • pregnant
  • consume >4 cups of tea/coffee per day
  • consume >5 portion of fruits and vegetables per day
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment group

    Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)

    Dietary Supplement: Chlorogenic Acid (CGA) enriched coffee

  • Sham comparator
    Control group

    Conventional coffee (habitual diet)

    Dietary Supplement: Conventional coffee

Interventions

  • Dietary supplementChlorogenic Acid (CGA) enriched coffee

    Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg. Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)

    Also known as: CGA-enriched diet

  • Dietary supplementConventional coffee

    Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice

    Also known as: Habitual diet

06

What researchers measure

Primary outcomes

  1. Change in glycohaemoglobin (HbA1c)

    Time frame: 3 months

  2. Change in estimated glomerular filtration rate (eGFR)

    Time frame: 21 months

Secondary outcomes

  1. Change in fasting glucose

    Time frame: 3 months

  2. Change in fructosamine

    Time frame: 3 months

  3. Change in advanced glycation end product (AGE)

    Time frame: 3 months

  4. Change in soluble receptor for AGE (sRAGE)

    Time frame: 3 months

  5. Change in F2-isoprostane

    Time frame: 3 months

  6. Change in malondialdehyde (MDA)

    Time frame: 3 months

  7. Change in Urinary Albumin Excretion

    Time frame: 21 months

  8. Change in creatinine

    Time frame: 21 months

  9. Change in blood pressure

    Time frame: 21 months

  10. Change in crystatin C

    Time frame: 21 months

  11. Change in fibrinogen

    Time frame: 21 months

  12. Change in cholesterol

    Time frame: 21 months

  13. Change in C-reactive protein

    Time frame: 21 months

  14. Change in Interleukin-6

    Time frame: 21 months

  15. Change in thiobarbituric acid reactive substances (TBARS)

    Time frame: 21 months

  16. Change in advanced oxidation protein products (AOPP)

    Time frame: 21 months

  17. Change in 8hydroxy 2'deoxyguanoside (8OhdG)

    Time frame: 21 months

07

Study locations

2 sites
  • NHS Greater Glasgow and Clyde
    Glasgow, United Kingdom
  • University of Glasgow
    Glasgow, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02524938
Lead sponsor
NHS Greater Glasgow and Clyde
Collaborators
University of Glasgow
Responsible party
Sponsor
First posted
Aug 17, 2015
Start date
Jun 1, 2016
Primary completion
Sep 2022
Completion
Sep 2022
Last update
Feb 10, 2023

Study contacts

Emilie Combet, PhD
principal investigator · University of Glasgow

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion